350
Y. Cheng and H. Jin
100. Menne J, Eulberg D, Beyer D, Baumann M, Saudek F, Valkusz Z, Wi˛ ecek A, Haller H (2017)
C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients
with albuminuria. Nephrol Dial Transplant 32(2):307–315
101. Shaw JP, Kent K, Bird J, Fishback J, Froehler B (1991) Modified deoxyoligonucleotides stable
to exonuclease degradation in serum. Nucleic Acids Res 19(4):747–750
102. Monia BP, Johnston JF, Sasmor H, Cummins LL (1996) Nuclease resistance and antisense
activity of modified oligonucleotides targeted to Ha-ras. J Biol Chem 271(24):14533–14540.
https://doi.org/10.1074/jbc.271.24.14533
103. Kuwahara M, Sugimoto N (2010) Molecular evolution of functional nucleic acids with
chemical modifications. Molecules 15(8):5423–5444
104. Li N, Nguyen HH, Byrom M, Ellington AD (2011) Inhibition of cell proliferation by an
anti-EGFR aptamer. PLoS ONE 6(6):e20299
105. Lebars I, Richard T, Di Primo C, Toulme JJ (2007) LNA derivatives of a kissing aptamer
targeted to the trans-activating responsive RNA element of HIV-1. Blood Cells Mol Dis
38(3):204–209. https://doi.org/10.1016/j.bcmd.2006.11.008
106. Sundaram P, Kurniawan H, Byrne ME, Wower J (2013) Therapeutic RNA aptamers in clinical
trials. Eur J Pharm Sci 48(1–2):259–271. https://doi.org/10.1016/j.ejps.2012.10.014
107. Bouchard PR, Hutabarat RM, Thompson KM (2010) Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50:237–257. https://doi.org/10.1146/annurev.
pharmtox.010909.105547
Y. Cheng and H. Jin
100. Menne J, Eulberg D, Beyer D, Baumann M, Saudek F, Valkusz Z, Wi˛ ecek A, Haller H (2017)
C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients
with albuminuria. Nephrol Dial Transplant 32(2):307–315
101. Shaw JP, Kent K, Bird J, Fishback J, Froehler B (1991) Modified deoxyoligonucleotides stable
to exonuclease degradation in serum. Nucleic Acids Res 19(4):747–750
102. Monia BP, Johnston JF, Sasmor H, Cummins LL (1996) Nuclease resistance and antisense
activity of modified oligonucleotides targeted to Ha-ras. J Biol Chem 271(24):14533–14540.
https://doi.org/10.1074/jbc.271.24.14533
103. Kuwahara M, Sugimoto N (2010) Molecular evolution of functional nucleic acids with
chemical modifications. Molecules 15(8):5423–5444
104. Li N, Nguyen HH, Byrom M, Ellington AD (2011) Inhibition of cell proliferation by an
anti-EGFR aptamer. PLoS ONE 6(6):e20299
105. Lebars I, Richard T, Di Primo C, Toulme JJ (2007) LNA derivatives of a kissing aptamer
targeted to the trans-activating responsive RNA element of HIV-1. Blood Cells Mol Dis
38(3):204–209. https://doi.org/10.1016/j.bcmd.2006.11.008
106. Sundaram P, Kurniawan H, Byrne ME, Wower J (2013) Therapeutic RNA aptamers in clinical
trials. Eur J Pharm Sci 48(1–2):259–271. https://doi.org/10.1016/j.ejps.2012.10.014
107. Bouchard PR, Hutabarat RM, Thompson KM (2010) Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50:237–257. https://doi.org/10.1146/annurev.
pharmtox.010909.105547